Press Releases

04.06.2016

Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13®

04.06.2016

Pfizer Announces Termination of Proposed Combination with Allergan

04.05.2016

FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications

04.05.2016

Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinom

04.05.2016

Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

04.04.2016

Pfizer and Allergan Issue Statement

04.04.2016

Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing

04.01.2016

Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab

03.31.2016

Pfizer Inc. (NYSE: PFE) today issued the following statement:

03.30.2016

Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination

03.30.2016

Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology’s 65th Annual Scientific Session

03.23.2016

Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ® (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis